InsiderTrades.com logo
JD Vance Predicts: Wall Street vs. Trump & Your Money
From Priority Gold   |   Ad
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Get your free guide NOW before it's too late.
Joseph M. Miller net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Joseph Miller Biography and Net Worth

CFO of Aurinia Pharmaceuticals
Joe Miller joins Aurinia with over two decades of experience as a senior executive managing financial operations and supporting enterprise growth in companies across the health sciences, biotech and pharmaceutical sectors. Most recently, he served as Chief Financial Officer, Principal Executive Officer, and Corporate Secretary at Cerecor, Inc. At Cerecor, he completed the acquisition of Ichorion Therapeutics, Inc., the purchase of Aevi Genomic Medicine, and facilitated a strategic transformation of the organization by leading the divestiture of the company’s commercial portfolio in a transaction with Aytu BioScience, Inc. in 2019. Joe currently serves as a director on Cerecor’s Board. Prior to Cerecor, Joe was the Vice President of Finance at Sucampo Pharmaceuticals, Inc., where he was responsible for building out the finance organization to effectively support the company’s rapid growth, ultimately leading to the $1.2B merger with Mallinckrodt in early 2018. Prior to Sucampo, he served in various progressive finance and management roles at QIAGEN, Eppendorf and KPMG LLP. Joe received his B.S. in accounting from Villanova University and is a Certified Public Accountant.

What is Joseph M. Miller's net worth?

The estimated net worth of Joseph M. Miller is at least $2.80 million as of March 2nd, 2023. Mr. Miller owns 331,214 shares of Aurinia Pharmaceuticals stock worth more than $2,798,758 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Miller may own. Additionally, Mr. Miller receives a salary of $883,190.00 as CFO at Aurinia Pharmaceuticals. Learn More about Joseph M. Miller's net worth.

How old is Joseph M. Miller?

Mr. Miller is currently 50 years old. There are 5 older executives and no younger executives at Aurinia Pharmaceuticals. The oldest executive at Aurinia Pharmaceuticals is Mr. Scott Habig, Chief Commercial Officer, who is 64 years old. Learn More on Joseph M. Miller's age.

What is Joseph M. Miller's salary?

As the CFO of Aurinia Pharmaceuticals Inc., Mr. Miller earns $883,190.00 per year. There are 2 executives that earn more than Mr. Miller. The highest earning executive at Aurinia Pharmaceuticals is Mr. Peter S. Greenleaf M.B.A., President, CEO & Director, who commands a salary of $1,570,000.00 per year. Learn More on Joseph M. Miller's salary.

How do I contact Joseph M. Miller?

The corporate mailing address for Mr. Miller and other Aurinia Pharmaceuticals executives is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. Aurinia Pharmaceuticals can also be reached via phone at 250-708-4272 and via email at [email protected]. Learn More on Joseph M. Miller's contact information.

Has Joseph M. Miller been buying or selling shares of Aurinia Pharmaceuticals?

Joseph M. Miller has not been actively trading shares of Aurinia Pharmaceuticals during the past quarter. Most recently, Joseph M. Miller sold 11,296 shares of the business's stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $8.94, for a transaction totalling $100,986.24. Following the completion of the sale, the chief financial officer now directly owns 331,214 shares of the company's stock, valued at $2,961,053.16. Learn More on Joseph M. Miller's trading history.

Who are Aurinia Pharmaceuticals' active insiders?

Aurinia Pharmaceuticals' insider roster includes Matthew Donley (VP), Peter Greenleaf (CEO), Robert Huizinga (EVP), Jill Leversage (Director), Michael Martin (Insider), Joseph Miller (CFO), and Neil Solomons (Insider). Learn More on Aurinia Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Aurinia Pharmaceuticals?

In the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 22,806 shares worth more than $135,317.70. The most recent insider tranaction occured on November, 11th when Director Jeffrey Allen Bailey sold 4,557 shares worth more than $38,415.51. Insiders at Aurinia Pharmaceuticals own 4.3% of the company. Learn More about insider trades at Aurinia Pharmaceuticals.

Information on this page was last updated on 11/11/2024.

Joseph M. Miller Insider Trading History at Aurinia Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/2/2023Sell11,296$8.94$100,986.24331,214View SEC Filing Icon  
5/11/2021Buy1,000$9.74$9,740.001,000View SEC Filing Icon  
See Full Table

Joseph M. Miller Buying and Selling Activity at Aurinia Pharmaceuticals

This chart shows Joseph M Miller's buying and selling at Aurinia Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aurinia Pharmaceuticals Company Overview

Aurinia Pharmaceuticals logo
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Read More

Today's Range

Now: $8.45
Low: $8.31
High: $8.50

50 Day Range

MA: $7.35
Low: $6.58
High: $8.49

2 Week Range

Now: $8.45
Low: $4.71
High: $9.74

Volume

579,826 shs

Average Volume

1,599,492 shs

Market Capitalization

$1.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45
JD Vance Predicts: Wall Street vs. Trump & Your Money
From Priority Gold   |   Ad
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Get your free guide NOW before it's too late.